# US 2016/0256386 A1 · Methods and compositions for localized agent delivery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256386 A1
- Document ID: US20160256386A1
- Status: Published application
- Kind: A1
- Application number: 15/015,464
- Filed: 2016-02-04
- Published: 2016-09-08
- Earliest claimed: 2008-11-24
- Assignees: Massachusetts Institute of Technology
- Applicants: Massachusetts Institute of Technology
- Inventors: Darrell J. IRVINE; Matthias STEPHAN; Jaehyun MOON; Anna BERSHTEYN
- Web page: https://patentgrep.com/patent/US20160256386A1

## CPC

- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 9/146: {with organic macromolecular compounds}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 9/5146: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides}
- A61K 9/5153: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/711: Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 38/19: Cytokines; Lymphokines; Interferons
- A61K 38/20: Interleukins [IL]
- A61K 38/2086: {IL-13 to IL-16}
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/32: T-cell receptors [TCR]
- A61K 40/4273: {Glycoprotein 100 [Gp100]}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/46: Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
- A61K 47/6901: {Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors}
- A61K 47/6911: {the form being a liposome}
- A61K 47/6937: {the polymer being PLGA, PLA or polyglycolic acid}
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C12N 5/0006: {Modification of the membrane of cells, e.g. cell decoration}
- C12N 5/0636: {T lymphocytes}
- C12N 5/0647: {Haematopoietic stem cells; Uncommitted or multipotent progenitors}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/87: Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- A61K 2035/124: {the cells being hematopoietic, bone marrow derived or blood cells}
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/57: Skin; melanoma
- C12N 2310/14: interfering nucleic acids [NA]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention provides compositions and methods for delivering agents to localized regions, tissues, or organs in vivo by conjugating agent-loaded nanoparticles to cells having homing capability. The agents may be therapeutic or diagnostic agents such as cancer chemotherapeutic agents and imaging agents respectively.

## Claims

### Claim 1

A biodegradable nanoparticle comprising maleimide groups on its exterior surface.

### Claim 2 (depends on 1)

The nanoparticle of claim 1, wherein the nanoparticle further comprises a lipid bilayer surface.

### Claim 3 (depends on 1)

The nanoparticle of claim 1, wherein the nanoparticle comprises a poly(lactide-co-glycolide) (PLGA) core.

### Claim 4 (depends on 1)

The nanoparticle of claim 1, wherein the nanoparticle further comprises an agent.

### Claim 5 (depends on 1)

The nanoparticle of claim 1, wherein the nanoparticle further comprises a plurality of agents.

### Claim 6 (depends on 4)

The nanoparticle of claim 4, wherein the agent is an antibody.

### Claim 7 (depends on 4)

The nanoparticle of claim 4, wherein the agent is an antigen.

### Claim 8 (depends on 4)

The nanoparticle of claim 4, wherein the agent is an adjuvant.

### Claim 9 (depends on 8)

The nanoparticle of claim 8, wherein the adjuvant is a TLR ligand.

### Claim 10 (depends on 4)

The nanoparticle of claim 4, wherein the agent is a nucleic acid.

### Claim 11 (depends on 10)

The nanoparticle of claim 10, wherein the nucleic acid is an siRNA.

### Claim 12 (depends on 4)

The nanoparticle of claim 4, wherein the agent is an anti-cancer agent.

### Claim 13 (depends on 4)

The nanoparticle of claim 4, wherein the agent is a cytokine.

### Claim 14 (depends on 4)

The nanoparticle of claim 4, wherein the agent is an interleukin.

### Claim 15 (depends on 5)

The nanoparticle of claim 5, wherein the plurality of agents comprises an antigen and an adjuvant.

### Claim 16 (depends on 5)

The nanoparticle of claim 5, wherein the plurality of agents comprises an adjuvant and an anti-cancer agent.

### Claim 17 (depends on 1)

The nanoparticle of claim 1, wherein the nanoparticle is 50-500 nanometers in diameter.

### Claim 18 (depends on 1)

The nanoparticle of claim 1, wherein the nanoparticle is about 150 nanometers in diameter.

### Claim 19 (depends on 1)

The nanoparticle of claim 1, in a lyophilized form.
